Browse the world's most comprehensive database of hedge fund investor letters, sorted by recent quarter. Access primary source research from leading institutional managers.
| Quarter | Letter Date | Fund Name | QTD | YTD | Tickers | Themes | Quick Take |
|---|---|---|---|---|---|---|---|
Buyside Digest is not affiliated with, and does not endorse, NCG SMID Cap Growth Strategy. This analysis is provided for institutional research purposes only and is not investment advice.
"NCG's SMID Cap strategy underperformed in Q4 2023 due to healthcare headwinds from GLP-1 concerns, though the firm added quality names across healthcare and technology. The Fed pivot broadened market participation but favored lower quality stocks."
Next Century Growth Investors' SMID Cap Growth strategy returned 4.84% in Q4 2023, underperforming the Russell 2500 Growth Index's 12.59% return. For the full year, the strategy gained 15.46% versus the benchmark's 18.93%. The underperformance was primarily driven by healthcare holdings, which were negatively impacted by investor concerns about GLP-1 drugs reducing medical interventions across the sector. The firm added ten new positions during the quarter, including healthcare names like Medpace, Natera, and DexCom, as well as technology companies like Braze and Guidewire Software. The Fed's pivot toward rate cuts in 2024 helped broaden market participation in November and December, though the rally was led by lower quality stocks that made it challenging for the strategy to keep pace. The firm maintains its focus on high-quality growth companies with strong fundamentals and continues to generate new investment ideas. With small cap valuations remaining reasonable compared to 2021 highs, the team believes their bottom-up stock picking approach will drive long-term outperformance.
Sign in or create a free account to unlock full commentary, extracted equity pitches, and direct outbound manager source links with your 3 quarterly credits.
Algorithmic conviction, macroeconomic posture, and risk appetite signals extracted from this quarterly letter with qualitative explanations.
Market Conviction
The manager expresses strong confidence in their bottom-up stock selection process, core investment philosophy, and long-term growth prospects despite underperformance in smaller cap strategies in 4Q23.
Growth Outlook
The manager notes a shift toward a soft-landing narrative boosted by the Fed's pivot, though remains mindful of lingering effects from monetary tightening and potential growth headwinds.
Risk Appetite
The firm maintains full equity exposure (1% cash) and actively added ten new growth positions, demonstrating a healthy willingness to take on fundamental risk in small/mid-cap equities.
Capital Deployment
Active portfolio turnover is evident through ten new position purchases and eight full exits, keeping cash levels near zero (1%).
Forward Guidance
The manager views small cap growth valuations as reasonable and sees upside potential from product rollouts and business recoveries heading into 2024.
Language Signal
The letter maintains a measured, confident tone, referencing 25 years of team experience navigating diverse economic cycles and sticking to direct research.
Perceived Risk
While acknowledging a choppy macro environment and restrictive Fed policy impacts, the manager considers small/mid-cap valuations reasonable relative to historical highs.
Opportunity Density
The manager highlights healthy new idea generation, citing the addition of ten new positions across healthcare, technology, and industrial sectors.
Time Horizon
The manager repeatedly stresses long-term business fundamentals, portfolio compounding, and holding quality growth companies across multi-year cycles.
